Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
:FOLD
FOLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.79 - $14.02
Previous CloseN/A
Volume320.41K
Average Volume (3M)2.17M
Market Cap
$2.92B
Enterprise Value$3.45B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Feb 19, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding298,805,800
10 Day Avg. Volume2,256,321
30 Day Avg. Volume2,172,556
Standard Deviation0.14
R-Squared0.05
Alpha0.00403
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.91
Price to Cash Flow (P/CF)-31.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.53
Enterprise Value/Ebitda-375.10
Forecast
1Y Price Target
$17.14Price Target Upside74.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
EarningsGalafold sales exceeded expectations, highlighting strong revenue performance.
Market ExpansionFOLD expects to expand into up to 10 new launch countries in 2025, broadening its market reach.
Regulatory ApprovalsAnticipated regulatory approvals in key markets like Japan, Australia, and Canada could significantly boost growth.
Bears Say
Revenue GuidanceFOLD's guidance for Pombiliti/Opfolda revenue growth falls below consensus estimates.
Revenue MissPreliminary Q4/FY24 global Pombiliti/Opfolda revenue slightly missed consensus estimates.
ValuationDespite strong 2024 performance, shares are viewed as fully valued at current levels, leading to a maintained Hold rating.
---
Ownership Overview
1.37% Insiders
32.30% Mutual Funds
38.07% Other Institutional Investors
11.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $8.79 and its highest was $14.02 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $2.92B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Feb 19, 2025 which is today.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.021.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is <0.01.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 298,805,800 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -4.259%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
---
Amicus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.14 (74.01% Upside)
$17.14 (74.01% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $75.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.41%
12-Months-Change
Fundamentals
Return on Equity
-67.09%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
FOLD Company Deck
---
FOLD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call displayed a positive sentiment with strong revenue growth, successful product launches, increased guidance, and achievement of non-GAAP profitability. While there are challenges like ongoing litigation and a decrease in cash reserves, they are outweighed by the strong financial and operational performance.Read More>---
FOLD Stock 12 Month Forecast
Average Price Target
$17.14
▲(74.01% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering FOLD
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+26.50%
reiterated a buy rating 3 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.50% per trade.
---